B

중앙백신

072020KOSDAQ

62.3 / 100

Reference Date: 2026-09-08

Financial Score25.5 / 40
News Sentiment18.8 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Central Vaccine is a company specializing in the development and production of animal vaccines and biological products, focusing on disease prevention and control in the livestock industry. Recent outbreaks of African Swine Fever and Highly Pathogenic Avian Influenza have increased demand for vaccines, necessitating the development of new products to counteract the diminishing efficacy of existing ones. The company is expanding into new markets, including China and Brazil, to broaden its global presence.

Number of Employees

194people

Average Salary

57.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
14.19Industry Average 15.005.0Point

In line with industry avg

PBR
0.82Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
5.89Industry Average 8.002.5Point

Below industry avg

Debt Ratio
5.08Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲8.3% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼2.6% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 6.3% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 75

Detailed Momentum

52-week position3.0Point

52w lower range (38%)

Current 9,310Won52-week high 10,14052-week low 8,780
1-month return3.0Point

1m 0.22% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral유동성공급계약의체결2026-08-18
  • Neutral반기보고서 (2026.06)2026-08-14